Choosing the right peptide compound for a research protocol starts with understanding what each compound is optimized for. This reference compares every compound in the CoreVionRX catalog across mechanism, primary research category, study window, and storage requirements.
Tissue Repair and Recovery
| Compound | Mechanism | Primary Research Area | Study Window |
|---|---|---|---|
| BPC-157 | GH receptor upregulation, angiogenesis, NO signaling | Tendon, ligament, gut, muscle repair | 2–6 weeks |
| TB-500 | Actin regulation, cell migration (Thymosin Beta-4) | Wound healing, cardiac tissue, corneal repair | 4–8 weeks |
| GHK-Cu | Copper-tripeptide, collagen synthesis, antioxidant | Dermal repair, extracellular matrix remodeling | 6–12 weeks |
Metabolic and GLP Compounds
| Compound | Mechanism | Primary Research Area | Study Window |
|---|---|---|---|
| Tirzepatide | Dual GIP/GLP-1 receptor agonist | Glycemic control, insulin sensitivity, weight regulation | 8–16 weeks |
| Retatrutide | Triple GIP/GLP-1/glucagon agonist | Metabolic syndrome, adipose reduction, glycemic control | 12–24 weeks |
| MOTS-c | Mitochondrial-derived peptide, AMPK activation | Insulin sensitivity, metabolic flexibility, aging | 4–8 weeks |
Cognitive and Neuroprotective
| Compound | Mechanism | Primary Research Area | Study Window |
|---|---|---|---|
| Semax | BDNF upregulation, dopamine modulation | Neuroprotection, cognitive performance, ischemic recovery | 10–30 days |
| PT-141 | Melanocortin receptor agonist (MC3R/MC4R) | Sexual function, CNS melanocortin signaling | Acute protocols |
Longevity and Immune
| Compound | Mechanism | Primary Research Area | Study Window |
|---|---|---|---|
| Epithalon | Telomerase activation, pineal regulation | Telomere length, circadian rhythm, longevity biomarkers | 10-day courses |
| Thymosin Alpha-1 | T-cell and dendritic cell activation | Immune modulation, viral and cancer model research | 4–8 weeks |
| NAD+ | Coenzyme, sirtuin and PARP activation | Mitochondrial function, DNA repair, metabolic aging | 4–8 weeks |
| Melanotan II | Non-selective melanocortin agonist | Pigmentation, appetite, sexual function (animal models) | 2–4 weeks |
Growth Hormone Axis
| Compound | Mechanism | Primary Research Area |
|---|---|---|
| CJC-1295 DAC | GHRH analog with Drug Affinity Complex (extended half-life) | GH pulse amplification, IGF-1 elevation studies |
| Ipamorelin | Selective ghrelin receptor agonist (GHS-R1a) | GH secretion, body composition research |
| CJC-1295 + Ipamorelin Blend | Dual GHRH + GHS pathway activation | Synergistic GH pulse research |
Research Blends
| Blend | Compounds | Primary Research Area | Size |
|---|---|---|---|
| GLOW | GHK-Cu + BPC-157 + TB-500 | Tissue repair, dermal remodeling, multi-pathway repair | 70mg |
| KLOW | Epithalon + Thymosin Alpha-1 + MOTS-c + NAD+ | Longevity, immune modulation, mitochondrial health | 80mg |
How to Choose Between Similar Compounds
BPC-157 vs TB-500
Both studied for tissue repair through distinct mechanisms. BPC-157 is faster-acting at the cellular level with broader systemic data. TB-500 has stronger data on cardiac tissue and wound healing surface area. Many researchers study both — see the GLOW blend for combined protocols.
Tirzepatide vs Retatrutide
Tirzepatide is the cleaner model for GIP/GLP-1 interaction without glucagon confounding. Retatrutide adds glucagon receptor agonism for maximal adipose mobilization studies.
CJC-1295 vs Ipamorelin vs the Blend
CJC-1295 acts upstream at the GHRH receptor. Ipamorelin acts downstream at the ghrelin receptor. They operate through different pathways — the combination blend produces synergistic GH effects in animal models.
Storage and Preparation
All CoreVionRX compounds ship as lyophilized powder. Use the peptide reconstitution calculator for accurate volumes. See the Peptide Storage Guide for full storage standards by compound type.
All information is for laboratory research purposes only. Not intended for human use.